OU researchers help new medicine's approval | Health
Researchers at the University of Oklahoma Health Sciences Center are being recognized for their role in research that led to the approval of an anti-clotting drug.
The U.S. Food and Drug Administration just expanded the approved use of Xarelto to include treating and preventing deep vein thrombosis or pulmonary embolism in patients.
“This will improve the care of an estimated 600,000 patients each year in the United States who require treatment for DVT or PE,” said Gary Raskob, Ph.D., dean of the OU College of Public Health.
Raskob and the OU Health Sciences Center oversaw clinical studies that evaluated the safety and effectiveness of the drug when treating those problems.
Researchers say Xarelto was as effective as standard treatments and reduced serious bleeding side effects.